bioRxivNeurosciencePreprint
AAV-mediated peripheral single chain variable fragments administration to reduce cerebral tau in adult P301S transgenic mice: mono- vs combination therapy
Sebica Katel, Julia Cicalo, Valeria VasciaveoiD, Joseph CarrióniD, Mahadeo Leann, Patricio T. HuertaiD, Philippe MarambaudiD, Luca GilibertoiD, Cristina d’AbramoiD
Abstract
Tau is a primary target for immunotherapy in Alzheimers disease. Recent studies have shown the potential of anti-tau fragment antibodies in lowering pathological tau levels in vitro and in vivo. Here, we compared the effects of single-chain variable fragments (scFv) derived from the well-characterized monoclonal antibodies PHF1 and MC1. We used adeno-associated virus 1 (AAV1) to deliver scFvs to skeletal muscle cells in eight-week-old P301S tau transgenic mice. We evaluated motor and behavioral functions at 16 and 23 weeks of age and measured misfolded, soluble, oligomeric and insoluble brain tau species. Monotherapy with scFv-MC1 improved motor and behavioral functions more effectively than scFv-PHF1 or combination therapy. Brain glucose metabolism also benefited from scFv-MC1 treatment. Surprisingly, combining scFvs targeting early (MC1) and late (PHF1) tau modifications did not produce additive or synergistic effects. These results confirm that intramuscular AAV1-mediated scFv-MC1 gene therapy holds promise as a potential treatment for Alzheimers disease. Our findings also suggest that combining scFvs targeting different tau epitopes may not necessarily enhance efficacy if administered together in a prevention paradigm. Further research is needed to explore whether other antibodies combinations and/or administration schedules could improve the efficacy of scFv-MC1 alone. Graphical abstract/eTOC synopsisKatel and colleagues show that peripheral vectorized scFvMC1 (in monotherapy) reduces pathological tau species in tau transgenic mice more efficiently than in combination with scFv-PHF1. The authors observed improved motor and behavioral functions together with increased brain glucose metabolism in scFv-MC1-treated mice. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=136 SRC="FIGDIR/small/638144v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@7edcccorg.highwire.dtl.DTLVardef@d1fc50org.highwire.dtl.DTLVardef@bf6f8org.highwire.dtl.DTLVardef@1832331_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- AAV-mediated neuronal expression of a scFv antibody selective for Aβ oligomers protects synapses and rescues memory in Alzheimer models
María Clara Sellés, Juliana T.S. Fortuna, … Sergio Teixeira Ferreira·Molecular TherapyPeer-reviewed·Nov 11, 2022
- Expression of amyloid-β antibody via AAV of CNS tropism alleviates Alzheimer's disease in mice
Zhong‐Min Dai, Min Jiang, … Mengsheng S. Qiu·bioRxiv·Mar 20, 2026
- Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathy.
Jonathan P. Hulse, Nicole M. Maphis, … Kiran Bhaskar·bioRxiv·Apr 5, 2024
- Clearing truncated tau protein restores neuronal function and prevents microglia activation in tauopathy mice
Alejandro Martín‐Ávila, Swananda Modak, … Einar M. Sigurdsson·Cell ReportsPeer-reviewed·Sep 17, 2025
- Delivery of mRNA encoding an anti-Tau monoclonal antibody and engineered scFv intrabody results in functional antibody expression in SH-SY5Y cells
Patricia Wongsodirdjo, Alayna C. Caruso, … Rebecca M. Nisbet·bioRxiv·Nov 15, 2023
- Restoring neurovascular coupling in Alzheimer's disease tauopathy through M1 mAChR modulation
Wesam Bassiouni, Moahmed Abdelnaby, … Khaled S. Abd‐Elrahman·bioRxiv·Aug 26, 2026